Diplomat Pharmacy (DPLO) Receives Media Sentiment Rating of 0.19
News headlines about Diplomat Pharmacy (NYSE:DPLO) have trended somewhat positive on Wednesday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Diplomat Pharmacy earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.9605126220564 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
A number of equities research analysts recently issued reports on DPLO shares. Robert W. Baird cut shares of Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $24.00 to $18.00 in a research report on Thursday, November 16th. Leerink Swann upgraded shares of Diplomat Pharmacy from a “market perform” rating to an “outperform” rating and set a $23.00 target price for the company in a research report on Monday, December 11th. Credit Suisse Group upgraded shares of Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and set a $28.00 target price for the company in a research report on Thursday, January 25th. Lake Street Capital started coverage on shares of Diplomat Pharmacy in a research report on Friday, February 9th. They set a “buy” rating and a $35.00 target price for the company. Finally, Mizuho set a $25.00 target price on shares of Diplomat Pharmacy and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Seven investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $23.95.
Shares of Diplomat Pharmacy (DPLO) opened at $23.42 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.34 and a quick ratio of 0.82. The firm has a market cap of $1,576.51, a PE ratio of 234.20 and a beta of 1.06. Diplomat Pharmacy has a 1 year low of $13.39 and a 1 year high of $27.78.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.